The CV safety of a lower dose of liraglutide (1.8 mg, Victoza, Novo Nordisk) in people with T2D was established in the Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results (LEADER) study, showing a 13% reduction in major CV events over an average of 3.8 years [44]
Neutralizes oxidative damage UV exposure, pollution, and metabolic stress create free radicals that age skin cells
The Journal of Dermatology, 36 (6), 323327
The Next Generation of Injectable Weight-Management Therapies: What Patients Need to Know Jaydev Varsani Clinical Prescribing Pharmacist Interest in medically supervised weight-management treatments has grown rapidly in recent years, and many patients visiting Bramley Pharmacy in Ealing are asking about the next wave of therapies currently being studied
No claims are made or implied regarding weight loss, metabolic benefits, therapeutic results, or human use
Sperb, L